ABSTRACT
Inflammatory bowel disease [IBD] is the consequence of an aberrant hemostasis of the immune cells at the gut mucosal border. Based on clinical manifestation, laboratory tests, radiological studies, endoscopic and histological features, this disease is divided into three main types including Crohn's disease [CD], Ulcerative colitis [UC], and IBDunclassified [IBD-U]. IBD is frequently presented in adults, but about 20% of IBD cases are diagnosed during childhood called pediatric IBD [PIBD]. Some patients in the latter group emerge the first symptoms during infancy or under 5 years of age named infantile and very early onset IBD [VEO-IBD], respectively. These subtypes make a small fraction of PIBD, but they have exclusive phenotypic and genetic characteristics such that they are accompanied by severe disease course and resistance to conventional therapy
In this context, understanding the underlying molecular pathology opens a promising field for individualized and effective treatment. Here, we describe current hypotheses on IBD pathophysiology then explain the new idea about genetic screening technology as a good potential approach to identify the causal variants early in the disease manifestation, which is especially important for the fast and accurate treatment of VEO-IBD